Clinical Trials on Advanced Esophageal Carcinoma

Total 30911 results

Imperial College London
Imperial College Healthcare NHS Trust

Recruiting

Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms (ViSON)

Oesophageal Squamous Cell Carcinoma | Oesophageal Cancer

United Kingdom
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (RAMONA)

Esophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer Nos

Germany
Yuhong Li

Completed

FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

Advanced Esophageal Carcinoma

China
Peking University

Unknown

mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

Advanced Esophageal Carcinoma

China
Sun Yat-sen University
Affiliated Cancer Hospital of Shantou University Medical College

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Esophageal Cancer | Oesophageal Cancer | Squamous Cell Esophageal Carcinoma

China
Jiangsu Cancer Institute & Hospital

Recruiting

Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus (SCALE-2)

Locally Advanced Esophageal Carcinoma

China
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd; Fiverings Co., Ltd.

Active, not recruiting

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

Japan
Peking University

Unknown

mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial

Advanced Esophageal Carcinoma

China
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Oesophageal Adenocarcinoma | Oesophageal Squamous Cell Carcinoma

Korea, Republic of, Belgium, Italy, United States, Chile, China, France, Netherlands, Spain
Cancer Institute and Hospital, Chinese Academy...
Akeso Pharmaceuticals, Inc.

Not yet recruiting

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Metastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Unknown

Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Carcinoma

China
Peking University

Unknown

Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial

Advanced Esophageal Squamous Carcinoma

China
West China Hospital

Not yet recruiting

Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.

Advanced Esophageal Squamous Carcinoma With Oligometastases
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Cell Carcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

China
Shanghai Chest Hospital

Recruiting

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma | Unresectable Locally Advanced Esophageal Cancer

China
Peking University

Recruiting

To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

Advanced Esophageal Squamous Cell Carcinoma

China
Hoffmann-La Roche

Active, not recruiting

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Korea, Republic of, Argentina, Denmark, France, Spain, Brazil, United Kingdom, Turkey, Czechia, Thailand, Russian Federation, Italy, Poland, Taiwan, Singapore, Ukraine, Kenya, Hungary
The Affiliated Hospital of Qingdao University

Recruiting

Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)

Gastric or Gastro-oesophageal Junction Carcinoma | Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma | Second-line Therapy

China
Peking University People's Hospital
Akeso Pharmaceuticals, Inc.

Not yet recruiting

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Xiangya Hospital of Central South University; Wuhan University; Zhujiang Hospital and other collaborators

Recruiting

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) (EC-CRT-007)

Locally Advanced Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study

Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital

Recruiting

Neo-NTP-CRT for Locally Advanced ESCC (Neo-NTP-CRT)

Locally Advanced Esophageal Squamous Cell Carcinoma

Taiwan
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute
First Affiliated Hospital Xi'an Jiaotong University; General Hospital of Ningxia... and other collaborators

Unknown

Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Zhigang Li
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial Of Neoadjuvant Chemotherapy or Radiochemotherapy With Or Without SHR-1210 In Patients With Resectable ESCC.

Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (Stars)

Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma

China
National Taiwan University Hospital

Recruiting

Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients

Locally Advanced Esophageal Squamous Cell Carcinoma

Taiwan
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Zhongshan People's Hospital... and other collaborators

Recruiting

Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) (EC-CRT-002)

Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

Radiotherapy | Sintilimab | Concurrent Chemoradiotherapy | Immunonutrition | Locally Advanced Esophageal Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Oesophageal Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Locally Advanced Unresectable Esophageal Squamous Carcinoma

China
Sun Jing

Not yet recruiting

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Locally Advanced Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute
Southwest Hospital, China; Affiliated Cancer Hospital & Institute of Guangzhou... and other collaborators

Unknown

Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma

China
European Organisation for Research and Treatment...

Terminated

Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL)

Inoperable œsophageal Cancer

Spain, France
RenJi Hospital

Recruiting

Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

Advanced Esophageal Squamous Cell Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Advanced Esophageal Squamous Cell Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

Esophageal Squamous Cell Carcinoma | Locally Advanced Carcinoma

China
Federation Francophone de Cancerologie Digestive
Shire

Active, not recruiting

Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma (OESIRI)

Squamous Cell Carcinoma

France
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditions

United States
Bristol-Myers Squibb

Completed

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Esophageal Squamous Cell Carcinoma

United Kingdom
CStone Pharmaceuticals

Active, not recruiting

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

China
Hansoh BioMedical R&D Company

Recruiting

HS-20093 in Patients With Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

Advanced Solid Tumor

China
Shandong Cancer Hospital and Institute

Recruiting

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Advanced Esophageal Squamous Cell Cancer

China
Shanghai Zhongshan Hospital

Recruiting

NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma (NATION1907II)

Oesophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Peking Union Medical College Hospital

Not yet recruiting

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Anlotinib | Advanced Esophageal Squamous Cell Cancer | SHR-1210

Clinical Trials on Advanced Esophageal Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations